Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

Gothenburg, the city of life science – We are ‘Little Boston’

Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...

Lonza

Ingrid Lönnstedt: ”The confidence interval and its width”

Always keep an eye on the width of your and others’ confidence intervals, writes Ingrid Lönnstedt in a science column.

A new life science cluster formed – “We are very strong in talent”

Stockholm and Uppsala’s joint life science cluster aims to be among the best in Europe. Pontus Holm, Life Science Coordinator for Region Stockholm, says the dec...

Ozempic may benefit hip replacement surgery

The high-profile drug for type 2 diabetes and weight loss may be beneficial in other areas. One such area is for patients undergoing hip replacement surgery, a ...

TECHNIA AB

What will be the next big hype after obesity? – An expert panel highlighted their top picks

What will be the next big trend in life science? Everything from Alzheimer’s, Crispr and Omics were highlighted when the issue was debated at this year’s major ...

A mass flow controller that is silent, fast and cost-effective

Portable ventilator breathing devices, bioreactors or the dosing of inert gases all rely on the highest control dynamics. That is exactly what the proportional ...

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

Superconductor technology: Contactless working in the laboratory of the future

Automated filling and weighing of freeze-dry containers in the cleanroom with SupraMotion from Festo

Discover the new ZEISS Axioscan 7 clinical

Your digital slide scanner for diagnostics & clinical research.

She is CSL Behring's new Nordic General Manager

Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.

Failed to read the fine print – lost his life’s work

A celebrated CEO and co-founder of a pioneering lab company one moment – the next, fired, kicked out and written out of the company’s history. This is the story...

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis

Free webinar organized by ZEISS.

Raised millions to develop a treatment for ´butterfly children´

Fragile as a butterfly’s wing – that’s how people living with Epidermolysis Bullosa are usually described. The Lund-based company Xinnate recently raised SEK 10...

Björn Arvidsson will lead research and innovation in Region Uppsala

The Swedish life science profile Björn Arvidsson has been appointed Director of Research and Innovation for Region Uppsala.

The New Precise Magazine is Available Now

Download the new issue.

GU Ventures AB

Artificial intelligence in radiology – “Risk prediction is very exciting”

A growing number of solutions based on artificial intelligence are being developed and used in healthcare. According to Sophia Zackrisson, Professor of Radiolog...

Ancient DNA provides new insights – “The immune system lost its job”

Ancient bone remains from our ancestors have provided new insights into the prevalence of multiple sclerosis. By looking back in time, researchers can provide a...

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

Setback for pharmaceutical companies in the Zantac case

A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.